$0.58
11.26% yesterday
Nasdaq, Jun 27, 10:11 pm CET
ISIN
US92536C1036
Symbol
VERU

Veru Inc Stock price

$0.58
+0.07 14.24% 1M
-0.09 13.95% 6M
-0.07 10.61% YTD
-0.22 27.31% 1Y
-12.28 95.48% 3Y
-2.85 83.05% 5Y
-1.38 70.33% 10Y
-0.97 62.48% 20Y
Nasdaq, Closing price Fri, Jun 27 2025
-0.07 11.26%
ISIN
US92536C1036
Symbol
VERU

Key metrics

Basic
Market capitalization
$85.2m
Enterprise Value
$65.2m
Net debt
$-20.0m
Cash
$20.0m
Shares outstanding
146.6m
Valuation (TTM | estimate)
P/E
- | negative
P/S
- | 28.82
EV/Sales
- | 22.05
EV/FCF
negative
P/B
4.05
Dividends
DPS
Yield 1Y | 5Y
- | -
Growth 1Y | 5Y
- | -
Payout 1Y | 3Y
- | -
Increased
-
Financials (TTM | estimate)
Revenue
- | $3.0m
EBITDA
- | -
EBIT
-
Net Income
- | $-32.3m
Free Cash Flow
$-29.2m
Growth (TTM | estimate)
Revenue
- | -82.49%
EBITDA
- | -
EBIT
-
Net Income
- | 14.58%
Free Cash Flow
26.76%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -1,091.77%
Free Cash Flow
-
Financial Health
Equity Ratio
53.49%
Return on Equity
-116.97%
ROCE
-
ROIC
-
Debt/Equity
0.00
More
EPS
FCF per Share
$-0.20
Short interest
10.18%
Employees
210.00
Rev per Employee
$80.00k
Show more

Is Veru Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Veru Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Veru Inc forecast:

9x Buy
82%
2x Hold
18%

Analyst Opinions

11 Analysts have issued a Veru Inc forecast:

Buy
82%
Hold
18%

Financial data from Veru Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
15 15
7% 7%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 28 28
34% 34%
191%
- Research and Development Expense 17 17
52% 52%
114%
-40 -40
42% 42%
-271%
- Depreciation and Amortization 0.26 0.26
7% 7%
2%
EBIT (Operating Income) EBIT -40 -40
42% 42%
-273%
Net Profit -38 -38
41% 41%
-261%

In millions USD.

Don't miss a Thing! We will send you all news about Veru Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Veru Inc Stock News

Neutral
GlobeNewsWire
17 days ago
MIAMI, FL, June 11, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced the company will be participating in one-on-one meetings and a fire side chat presentation with investors at the virtual BTIG Obesity Health Forum on June ...
Neutral
GlobeNewsWire
about one month ago
--Phase 2b QUALITY clinical study topline safety data shows that the enobosarm + semaglutide combination had a positive safety profile compared to semaglutide alone-- --Based on Phase 2b QUALITY trial efficacy and safety data, enobosarm 3mg will advance as the proposed oral dose for the Phase 3 clinical program-- -- Enobosarm 3mg + semaglutide combination had the added benefit of fewer gastroin...
Positive
Seeking Alpha
about one month ago
Veru Inc. has pivoted to focus on preventing lean mass reduction in patients using GLP-1 agonists, leveraging its lead asset, enobosarm. A Phase 2b trial showed that a 3mg dose of Enobosarm reduces lean mass loss by 99%, preserves physical function, and enhances selective fat loss when combined with semaglutide (Wegovy). VERU's lean balance sheet, with $20 million in cash and no debt, positions...
More Veru Inc News

Company Profile

Veru, Inc. is an oncology and urology biopharmaceutical company. It develops medicines for prostate cancer treatment and prostate cancer supportive care as well as urology specialty pharmaceuticals. Its oncology drug candidates includes VERU-111, an oral alpha and beta tubulin inhibitor, which is in a phase 1b/2 study for the treatment of metastatic castration resistant prostate cancer; Zuclomiphene citrate, which is in a phase 2 clinical trial for the treatment of hot flashes in men undergoing prostate cancer hormonal therapies; and VERU-100, a long-acting GnRH antagonist 3 month subcutaneous depot, planned phase 2 clinical trial for the treatment of hormone sensitive advanced prostate cancer. The company's urology specialty pharmaceutical drug candidate is TADFIN, a tadalafil and finasteride combination oral capsule, for the treatment of men with benign prostatic hyperplasia. Its commercial products include the FC2 Female/Internal condom for prevention of pregnancy and sexually transmitted infections and PREBOOST 4% benzocaine wipes for the prevention of premature ejaculation marketed as Roman Swipes by getroman.com. The company was founded by William R. Gargiulo Jr. and O.B. Parrish in 1996 and is headquartered in Miami, FL.

Head office United States
CEO Mitchell Steiner
Employees 210
Founded 1971
Website verupharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today